Dyadic International (DYAI) Q3 2025 earnings summary

Executive summary

• Transitioned from R&D-focused to a commercially driven biotechnology company, rebranding as Dyadic Applied BioSolutions in August 2025 and launching a new website to enhance commercial and investor engagement.

• Expanded product portfolio in life sciences, food nutrition, and bio-industrial segments, with multiple product launches, global partnerships, and commercial efforts in Asia underway.

• Integration of CRISPR-Cas9 gene editing via ERS Genomics license enhances strain optimization and productivity.

• Achieved key milestones in food, nutrition, and legacy collaborations, including Gates Foundation and CEPI grants, and received first purchase orders in cell culture media and molecular biology reagent segments.

• Strategic partnerships in Asia-Pacific and with industry leaders support global market penetration and recurring revenue opportunities.

Financial highlights

• Q3 2025 total revenues decreased to $1.17M from $1.97M year-over-year, mainly due to lower license and milestone revenue; nine-month revenue was $2.52M, down from $2.68M.

• Net loss for Q3 2025 increased to $1.98M ($0.06/share) from $0.20M ($0.01/share) year-over-year; nine-month net loss widened to $5.80M from $4.26M.

• Cash, cash equivalents, restricted cash, and investment-grade securities totaled $10.4M as of September 30, 2025, up from $9.3M at year-end 2024, supported by a $4.9M public offering.

• Operating expenses rose, with R&D at $572K (Q3) and $1.70M (nine months), and G&A at $1.48M (Q3), driven by rebranding, business development, and increased research initiatives.

• Gross margin for Q3 2025 was approximately 22%, impacted by lower license/milestone revenue and increased grant-related costs.

Outlook and guidance

• Anticipates growth in product revenue in life sciences and food/nutrition markets for the remainder of 2025, with operating expenses expected to remain in line with the prior year.

• Multiple product launches in cell culture media, molecular biology reagents, and animal-free proteins are expected to drive near-term revenue.

• Focus remains on accelerating sales, expanding global customer engagement, and advancing commercialization in core segments.

• Existing liquidity of $10.4M expected to cover operational needs for at least the next 12 months; ongoing losses and negative cash flows anticipated as commercialization continues.

• Additional capital may be sought through equity, debt, or collaborations if needed.